MTD vs SNY: fair value comparison
Mettler-Toledo International Inc. and Sanofi · Updated 2026-10-19
SNY reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, MTD currently ranks higher by quality score.
| MTD | SNY | |
|---|---|---|
| Verdict | Fairly valued | Awaiting full valuation |
| Last price | $1,549.99 | $40.67 |
| 12-month range | $1,025.53–$1,639.04 | $39.12–$52.34 |
| Rank by discount to fair value | #52 of 108 Healthcare | — |
| Rank by quality score | #121 of 301 Healthcare | #122 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | High | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: MTD fair value analysis · SNY fair value analysis